Brexit panic is good news for bargain hunters

Professional investor William Meadon picks three of his favourite UK stocks.

A professional investor tells us where he'd put his money. This week: William Meadon of the JP Morgan Claverhouse Investment Trust picks three favourites.

There is a great deal of uncertainty surrounding the British economy and stockmarket. But despite all the doom and gloom, the economy is in better shape than many realise. Indeed, in stark contrast to the horror stories and negative headlines, what we're seeing on the ground, at the company level, are a number of bright spots. It's easy to miss these opportunities if you don't tune out the Brexit-related noise.

JPMorgan Claverhouse aims to provide both capital and income growth for its shareholders by investing in a portfolio of 60 to 80 quoted British equities: reasonably valued quality companies with improving prospects. The fund has just announced its 46th consecutive annual dividend increase, the longest of any UK-only investment trust quoted on the London Stock Exchange.

The housing gloom has gone too far

What's more, the Help-to-Buy programme is making house purchases more accessible and, if the scheme finishes as planned in 2023, there should be an increasing number of people taking advantage of it in the coming years. We particularly like Barratt Developments (LSE:BDEV) thanks to its strategy of focusing on areas outside London, where there is less concentrated Brexit risk and, consequently, lower house-price volatility. Barratt's management are experienced, astute operators and although the 8% dividend yield on the shares includes some special payments, even in the absence of these the shares looks attractive.

New managers will boost Glaxo

GlaxoSmithKline (LSE:GSK)

However, a change in management should gradually improve the reputation of the company. In the meantime, investors are being paid generously to wait through the quarterly payment of a dividend currently worth more than 5% of the share price. Furthermore, the recent joint venture with Pfizer's consumer health business highlights the strategic choices available to the company and the management's ability to exploit them.

A top record in infrastructure

John Laing Group (LSE: JLG)

Recommended

Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Feb 2021
How to prepare your business for Brexit
Small business

How to prepare your business for Brexit

Whether we have a Brexit deal or not, new procedures for importers and exporters will apply from 1 January. Get your business ready now.
27 Nov 2020
Three winning stocks for a post-pandemic world
Share tips

Three winning stocks for a post-pandemic world

Professional investor Dan Lane of Freetrade selects three stocks that he thinks will keep their relevance in a changing world.
1 Mar 2021
DR Horton: US housebuilder that's piling up profits
Trading

DR Horton: US housebuilder that's piling up profits

US housebuilder DR Horton’s stock rests on firm foundations and looks cheap. Matthew Partridge looks at the best way to play it.
26 Feb 2021

Most Popular

A beginner’s guide to bitcoin: how to buy bitcoin
Bitcoin

A beginner’s guide to bitcoin: how to buy bitcoin

For the novice, buying bitcoin can be a daunting prospect. Here, Dominic Frisby outlines the process from start to finish.
2 Mar 2021
A beginner’s guide to bitcoin: what is bitcoin?
Bitcoin

A beginner’s guide to bitcoin: what is bitcoin?

As a completely novel concept for many people, bitcoin can take a little effort to get to grips with. In the first of a short series on the cryptocurr…
1 Mar 2021
Why gold has been such a bad investment so far this year
Gold

Why gold has been such a bad investment so far this year

Gold – the ultimate safe haven investment – is proving anything but safe. It’s lost over $200 an ounce since its high at the start of the year. Domini…
3 Mar 2021